Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Volumn 33, Issue 4, 2012, Pages 957-966

  Wang, Ying Xue ^a   Gao, Jin Xiang ^b   Wang, Xiu Yun ^b   Zhang, L ^b   Liu, Chang Mei ^b  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; NCOA3 PROTEIN, HUMAN; NIMOTUZUMAB; PYRAZOLE DERIVATIVE; STEROID RECEPTOR COACTIVATOR 3; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CADHERINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTROGENS; FEMALE; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; NUCLEAR RECEPTOR COACTIVATOR 3; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 85027944719     PISSN: None     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0324-4     Document Type: Article

References (0)